Balanced Immune Cell Culture via Anti-CD16 and Anti-CD3 Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional cellular immunotherapy methods fail to enhance immunocompetence by only differentiating mononuclear cells into a single type of immune cell, such as cytotoxic T cells, rather than achieving a well-balanced differentiation into multiple types like NK cells, NKT cells, and T cells.
Innovation Solution
A method involving specific cell culture steps using a culture medium with anti-CD16 monoclonal antibody and IL-2 or IL-15 to differentiate mononuclear cells into NK cells and NKT cells, followed by culturing in the presence of anti-CD3 antibody to preferentially stimulate cytotoxic T cells, ensuring a balanced proliferation of immune cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mononuclear cells are differentiated into a single type of immune cell (e.g., cytotoxic T cells) as in conventional cellular immunotherapy, then the differentiation process is simple and focused, but immunocompetence in vivo is not necessarily enhanced and the immune response is insufficient
Solution Approach 1:
The cell culture process is segmented into distinct phases: a first culture phase using anti-CD16 monoclonal antibody and IL-2/IL-15 to generate NK cells and NKT cells, followed by a second culture phase using anti-CD3 antibody to expand T cells. This segmentation allows each phase to target specific immune cell types, ensuring comprehensive immunocompetence enhancement while maintaining manageable process complexity through structured methodology
Solution Approach 2:
The invention changes cultural parameters (antibody types, cytokine combinations, culture conditions) between phases to direct differentiation toward multiple immune cell types. By adjusting these parameters systematically, the process achieves reliable immunocompetence enhancement through balanced production of NK cells, NKT cells, and T cells without requiring overly complex procedures
2Reliability
If multiple types of immune cells are differentiated in a well-balanced manner, then immunocompetence is effectively enhanced, but the culture conditions and process control become more complex
Solution Approach 1:
The culture process is designed as a dynamic two-phase system where conditions are adjusted at specific transitions. The first phase dynamically generates NK and NKT cells under anti-CD16/IL-2 or IL-15 conditions, then transitions to the second phase for T cell expansion under anti-CD3 conditions. This dynamic approach enables balanced multi-type immune cell production while maintaining operational ease through clear phase transitions and standardized protocols
3Productivity
If conventional single-type immune cell therapy is used, then the treatment protocol is simpler, but the therapeutic effect is limited and may not sufficiently enhance patient immunocompetence
Solution Approach 1:
The invention merges multiple immune cell types (NK cells, NKT cells, and T cells) into a single therapeutic product through a coordinated two-phase culture process. The first phase merges NK and NKT cell generation, while the second phase merges T cell expansion, creating a comprehensive immunotherapy product that delivers enhanced therapeutic effectiveness despite the increased manufacturing process complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method efficiently differentiates and proliferates mononuclear cells into NK cells, NKT cells, and T cells in a well-balanced manner, reducing the burden on patients by requiring less blood volume and minimizing the need for multiple apheresis procedures, while maintaining cellular cytotoxicity and antitumor activity.
Implementation Method 1
culturing mononuclear cells in a culture medium containing anti-CD16 monoclonal antibody and any one of IL-2, IL-15 or IL-2 and IL-15 to differentiate the mononuclear cells into at least NK cells and NKT cells
Implementation Method 2
performing culturing after the first step under conditions where the mononuclear cells are preferentially differentiated into cytotoxic T cells; wherein the second step is performed in the presence of anti CD3 antibody
Data Source
Figure 1(A)~1(B-2)
Figure 2(A)~2(B)
Figure 3
AI summary
To provide a method in which mononuclear cells are differentiated into a good balance of NK cells, NKT cells, and T cells, and said cells are made to proliferate. The present invention provides a method for manufacturing an immune cell-containing composition, said method including the following steps: a first step in which mononuclear cells are cultured in a medium containing anti-CD16 monoclonal antibodies and either IL-2 and/or IL-15; and a second step, after the first step, in which culturing is performed under conditions that make the mononuclear cells preferentially differentiate into cytotoxic T cells. This method may also include a third step, after the second step, in which culturing is performed in a medium containing anti-CD16 monoclonal antibodies and either IL-2 and/or IL-15.